Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide (Human) (C terminal).|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||Assay dependent|
|Immunoprecipitation (IP)||Assay dependent|
|Western Blot (WB)||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-30399 detects p21 from mouse, rat, and human samples.
PA1-30399 has been successfully used in immunohistochemistry (frozen tissue), immunoprecipitation, and Western blot applications.
The PA1-30399 immunogen is synthetic peptide (Human) (C terminal).
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CAP20; CDK-interacting protein 1; CDK-interaction protein 1; CDKN1; CDNK1A; cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A (P21); cyclin-dependent kinase inhibitor 1A (p21, Cip1); cyclin-dependent kinase inhibitor 1A variant 1; cyclin-dependent kinase inhibitor 1A variant 2; DNA synthesis inhibitor; MDA-6; melanoma differentiation associated protein 6; melanoma differentiation-associated protein; p21<WAF1/CIP1>; p21CIP1; SDI1; WAF1; wild-type p53-activated fragment 1
CAP20; CDKI; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; P21; p21CIP1; p21WAF; PIC1; SDI1; UV96; WAF1